Company intelligence / Profile preview

APEX Pharma

Ownership: Private
Employees: ~1500
Development stage: Other

Overview

APEX Pharma is among the largest generic pharmaceutical manufacturers in Egypt, ranked fifth in total sales by IQVIA in 2024 with rapid double-digit market growth, a diverse portfolio of over 200 branded generics, and significant manufacturing expansion ongoing in Egypt and new operations in Saudi Arabia

Therapeutic areas: RheumatologyMen's HealthInfectious DiseasesDermatologyCardiovascularOtherNeurologyWomen's Health
Modalities: Small moleculeBiologic
Industry: Biotech

Drug pipeline

4 assets

Ravanex

Unknown

3 more assets in the full pipeline.

Partnerships

Saudi Arabian government/authorities (localization agreement for manufacturing in King Abdullah Economic City)

Beyond the preview

Go deeper on APEX Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APEX Pharma.